Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real
innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that …

It is widely claimed that research to discover and develop new pharmaceuticals entails high
costs and high risks. High research and development (R&D) costs influence many decisions …

This essay reviews work in sociology and cognate fields regarding pharmaceutical
marketing and its regulation. In particular, it considers how this literature contributes to a …

How do organized economic interests affect the governance of the coronavirus disease
2019 (Covid-19) pandemic? We investigate whether the structural and instrumental power of …

Most existing studies on the role of business in global governance conceive of business as
one group acting vis-à-vis the state or NGOs. This article highlights that conflicts within the …

Background: Creating new therapies often involves drug companies paying healthcare
professionals and institutions for research and development (R&D) activities, including …

Purpose Pharmaceutical marketers use detailing, sampling and direct-to-consumer
advertising (DTCA) to promote a branded prescription drug (brand drug) to health-care …

Introduction: Pharmaceutical regulation has always attempted to balance the public health
objective to make safe and effective drugs available for patients while providing commercial …

The 2010 US reforms addressed forms of public and private insurance designed to reinforce
a delivery system that developed to maximize the autonomy of physicians and hospitals …

Since the adoption of the WTO‐TRIPS Agreement in 1994, there has been significant
controversy over the impact of pharmaceutical patent protection on the access to medicines …